Overview
Elucid Bioimaging provides an AI-powered SaaS platform that helps clinicians diagnose and manage cardiovascular disease by analyzing coronary CT angiography images to quantify plaque and model the coronary arteries. PlaqueIQ uses machine learning trained on paired CCTA data and histology to identify plaque types, create a 3D artery model, and move toward non-invasive FFR measurements (FFRCT). The product stands out by using histology-grounded AI with FDA 510(k) clearance and CE marking, offering more detailed plaque characterization than many competitors. The company aims to expand sales in North America and Europe to enable precision cardiology and preventive treatment, with the goal of reducing heart attacks and strokes.
Work here?Claim your company
Simplify's take
What believers are saying
- September 2, 2026 Series D raised $55 million for commercial expansion.
- September 29, 2026 Mark Miller joined as CRO to push sales execution.
- July 9, 2026 AI-PREDICT multicenter enrollment expands evidence across U.S., Europe, and Asia.
What critics are saying
- HeartFlow and Cleerly commoditize FFR-CT and plaque analytics before Elucid scales.
- October 2026 clearance still depends on hospitals adopting new reporting workflows fast.
- If payers deny broad utilization, Elucid remains a niche imaging vendor despite FDA wins.
What makes Elucid unique
- Plaque-IQ tied CTA findings to histology, not Hounsfield thresholds, since 2013.
- October 21, 2026 FFR-IQ combines anatomy, plaque biology, and physiology in one workflow.
- January 1, 2026 CPT coverage and Europe CE-marking support real-world reimbursement.
Help us improve and share your feedback! Did you find this helpful?